Irbesartán Kern Pharma (Irbesartan)

Irbesartan works by selectively blocking the angiotensin II type 1 (AT1) receptors on blood vessels, adrenal glands and kidney cells. This inhibition prevents angiotensin II‑mediated vasoconstriction and aldosterone release, leading to vessel relaxation, reduced sodium retention, and ultimately lower blood pressure.

The appropriate dose of irbesartan is determined by the prescribing clinician based on the individual’s blood pressure, kidney function, and other health factors. The prescriber will select a starting dose and may adjust it during follow‑up visits to achieve optimal blood‑pressure control.

Irbesartan is generally not recommended during pregnancy because it may affect fetal development. Limited data are available for breastfeeding mothers, so the drug should only be used if the potential benefit outweighs the risk. Patients should discuss any pregnancy or lactation plans with their healthcare provider.

To order Irbesartán Kern Pharma, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Irbesartan belongs to the ARB class, which offers blood‑pressure control similar to ACE inhibitors but with a lower incidence of cough and angioedema. Compared with calcium‑channel blockers, ARBs target the renin‑angiotensin system directly. Choice of therapy depends on patient tolerance, comorbidities and physician preference.

Irbesartan tablets should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability throughout its shelf life.

Irbesartan is taken orally, usually once daily. The tablet should be swallowed whole with a glass of water and can be taken with or without food. Patients should follow the dosing instructions provided by their prescriber and not split or crush the tablet unless advised.

The most serious adverse reactions to monitor are angioedema (swelling of the face, lips, tongue or throat), hyperkalemia (elevated potassium levels that can affect heart rhythm), and acute renal failure or a sudden decline in kidney function, especially when combined with other renin‑angiotensin system inhibitors.

Irbesartan should be avoided in patients with known hypersensitivity to the drug, those with bilateral renal artery stenosis, severe hepatic impairment, or in individuals who are pregnant. Caution is also advised for patients with existing hyperkalemia or severe kidney disease.